215 results about "Gemcitabine" patented technology

The invention discloses application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating diffuse large B-cell lymphoma. The drug combination comprises the anti-CD20 antibody drug conjugate, gemcitabine and oxaliplatin, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.

The invention discloses a nitroreductase response fluorescence and magnetic resonance bimodal probe NO2-Cy-Gxtb-Gd-Biotin designed on the basis of a gemcitabine prodrug as well as a synthesis method and application of the nitroreductase response fluorescence and magnetic resonance bimodal probe NO2-Cy-Gxtb-Gd-Biotin. The probe has relatively low fluorescence signals and magnetic resonance signals, and has relatively low biotoxicity. After the nitroreductase responds, on one hand, the gemcitabine anti-cancer drug is released, and tumor cell apoptosis is promoted; on the other hand, a molecular skeleton can generate a series of electron transfer to form an intermediate structure of methylquinone, and the intermediate structure of methylquinone is very high in reaction activity and is easily attacked by an external residue nucleophilic group of protein, so that the probe is anchored on nitroreductase, and a fluorescence signal and a magnetic resonance signal are remarkably enhanced; therefore, tumor enrichment is increased, an imaging time window is expanded, and early monitoring of tumors is facilitated. The medicine and the imaging probe are integrated, so that the treatment of monitoring tumors is facilitated.

The invention discloses a novel application of a composition of oleic acid, linoleic acid and Brusol or gemcitabine. According to the invention, oleic acid and linoleic acid are combined with different anti-tumor drugs, a pharmaceutical composition with a synergistic effect is screened out, and test results show that when oleic acid and linoleic acid in a specific proportion are combined with Brusol or gemcitabine, unexpected synergistic anti-pancreatic cancer activity can be obtained. The composition is expected to be developed into a new antitumor drug, can reduce the dosage of the antitumor drug, reduce drug resistance, reduce adverse reactions and improve the life quality of patients, and has important application prospects.

The present disclosure is related to a conjugate of an active drug and a glycosaminoglycan, such as hyaluronic acid (HA). For example, the active drug can be lenalidomide, nimesulide, or gemcitabine. The conjugate of the present disclosure is useful in the treatment of certain cancers.

The invention discloses a compound liposome, a freeze-dried powder injection as well as a preparation method and application of the freeze-dried powder injection. The compound lipidosome comprises a lipidosome membrane and an inner water phase encapsulated in the lipidosome membrane, the paclitaxel palmitate is encapsulated in a lipid bilayer of the liposome membrane; the gemcitabine or the salt thereof is encapsulated in the inner water phase; the compound liposome comprises the following raw materials: paclitaxel palmitate, lecithin, a polyethylene glycol derivative, gemcitabine or a salt thereof, an organic solvent and a buffer solution A; the molar ratio of the lecithin to the polyethylene glycol derivative is 1: (0.01-0.15). The compound liposome disclosed by the invention is relatively high in encapsulation efficiency (especially the encapsulation efficiency of PTX-PA is relatively good) and relatively high in safety, the preparation method is simple and easy to operate, the industrialization degree is high, and the prepared compound liposome has a relatively good long-circulation effect, a relatively good anti-tumor effect and good in-vivo tolerance.

A gemcitabine liposome pharmaceutical composition, a preparation method therefor and use thereof. According to the preparation method for the liposome, by means of optimization and control of the proportion of phospholipid to cholesterol, the proportion of the total lipid to an optional long circulating functional material, the proportion of the total lipid to a drug, and the type and the concentration of a salt solution in an aqueous interior, a liposome, which has high encapsulation efficiency, good storage stability, and high filtering performance, is not easy to leak, is stable and controllable to release, prolongs the half-life remarkably, improves the therapeutic effect, and reduces toxic and side effects, is prepared. In addition, the provided liposome prescription and preparation process are simple, and scaled-up production and clinical popularization and application are facilitated.

Disclosed is a compound represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof. The variables of structural formula (I) are described herein. The compound of the invention can be attached to chelating groups for radionuclide binding and are therefore suitable for radioimaging and / or radiotherapy applications, for example the disclosed compounds can be radiolabeled with a positron emitter such as 18F, 68Ga or 64Cu, and used for positron emission tomography (PET). Alternatively, the compounds can be radiolabeled with an alpha particle emitter such as 225 Ac, a beta particle emitter such as 67Cu or 177Lu, or an Auger electron emitter (e.g. 111In, 67Ga, 99mTc, 195mPt, 125I and 123I). The compounds can also be attached to a cytotoxic agent for targeted delivery of the cytotoxic agent to tumors, for example conjugated to gemcitabine or doxycycline, or a venom. Likewise, the compounds can be conjugated to compounds having physiological effects, such as TLR agonists to stimulate the immune response of a recipient.

The invention relates to the field of biology, and provides a human immortalized pancreatic cancer fibroblast as well as a preparation method and application thereof.The human immortalized pancreatic cancer fibroblast comprises three cell strains which are all primary fibroblast cells extracted from tumor tissues of pancreatic ductal adenocarcinoma patients, the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are classified and named as the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 respectively, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are all Cell STR identification and immunofluorescence detection prove that the cell strain is a fibroblast cell strain. After the tumor-associated fibroblast and pancreatic cancer cells are co-cultured, the proliferation ability of the tumor cells is obviously enhanced, and the sensitivity of the tumor cells to a chemotherapeutic drug gemcitabine is reduced. A new thought is provided for diagnosis and treatment of pancreatic cancer, and based on the pancreatic cancer in-vitro co-culture model established in vitro, the application has important significance for researching the effect and related mechanisms of fibroblasts in the pancreatic cancer tumor microenvironment.

Disclosed is an anticancer composition using a flavone derivative. In the present invention, the flavone derivative exhibits cytotoxicity against: H827, H1299, H522, and A549, which are human non-small cell lung cancer cell lines; MCF-7, which is a human breast cancer cell line; and PANC-1, which is a human pancreatic cancer cell line, in a time-dependent manner and in a treatment concentration-dependent manner, and not only exhibits a synergistic effect when used in combination with other conventional anticancer agents, such as osimertinib, which is an anticancer agent targeting for lung cancer, tamoxifen, which is a hormone agent against breast cancer, and gemcitabine, which is a cytotoxic anticancer agent against pancreatic cancer, but also exhibits the effect of synergistically inhibiting the expression of HIF-1α when used alone or in combination with an existing anticancer agent.

The invention relates to the technical field of biology, in particular to a human cholangiocarcinoma drug-resistant cell line HuCCT1-GEM-2 and application thereof.The human cholangiocarcinoma drug-resistant cell line HuCCT1-GEM-2 is preserved in the China Center for Type Culture Collection on May 11, 2023, the preservation number is CCTCC NO: C2023103, the IC50 value of the human cholangiocarcinoma drug-resistant cell line HuCCT1-GEM-2 to gemcitabine is 314.5 mu M, the IC50 value of a parent cell HUCCT1 to gemcitabine is 12.7 mu M, the drug-resistant index is up to 24.8, and the human cholangiocarcinoma drug-resistant cell line HuCCT1-GEM-2 can be used as a drug-resistant cell line. The cell body is obviously enlarged and rounded or is more irregular in shape, the specific volume of the cell cytoplasm is larger, binuclear or multinuclear appears in the cell, and the drug-resistant cell presents obvious bulk aggregation growth; after 24 hours, the growth rate of the HuCCT-1-GEM-2 cell is obviously slower than that of a parent cell, and the HuCCT-1-GEM-2 cell can be used for researching the drug resistance mechanism of bile duct cancer.

The invention belongs to the technical field of medicines, and particularly relates to application of leucine in preparation of anti-cancer drugs and chemotherapy sensitizers. According to the application provided by the invention, the leucine is applied to products of anti-cancer drugs and chemotherapy sensitizers, and the result shows that the IC50 of the chemotherapy drugs to cancer cells is remarkably reduced by adding the leucine, the chemotherapy sensitivity of the cancer cells to the chemotherapy drugs such as gemcitabine and oxaliplatin is improved, the resistance of the cancer cells to chemotherapy is reduced, and the curative effect of the cancer cells is improved. The improvement of the chemotherapy curative effect is facilitated.

Provided are siRNA compositions comprising gemcitabine (GEM) substituted for cytosine moieties in siRNAs. Provided are pharmaceutical compositions containing these siRNA molecules, and methods of using these compositions to treat diseases, such as cancer.

The invention discloses application of carboxamidotriazole combined chemotherapeutic drugs in preparation of drugs for treating solid tumors, which mainly aims at the chemotherapeutic drugs such as gemcitabine, docetaxel or albumin paclitaxel to achieve the technical effects of effect enhancement and toxicity reduction, and the solid tumors are lung cancer, breast cancer, liver cancer and kidney cancer. In-vivo and in-vitro researches prove that the combination of carboxamidotriazole and gemcitabine, docetaxel or albumin paclitaxel can achieve a remarkable combined synergistic effect, and does not increase toxic and side effects, so that the carboxamidotriazole can benefit more patients through clinical combined medication.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

The application discloses a LYTAG-Gem compound for enhancing the anti-tumor effect of gemcitabine and application thereof, relates to the technical field of biological medicine, and particularly relates to a gemcitabine (Gem) targeted delivery system based on a lysosome targeting chimera (LYTAC) and application thereof in enhancing the anti-tumor process. 2+ The system is assembled from heavy chain ferritin, Ni 2+ , NTA-PEG5000-DBCO and a targeting ligand TPP-1-N3 in a specific mass percentage, can efficiently load Gem and form a nano compound with a particle size of about 59-79 nm, the system targets tumor cells through heavy chain ferritin, and realizes site-specific release of Gem in cells by means of an endocytosis-lysosome pathway mediated by the LYTAC structure, in-vivo pharmacodynamic experiments show that the LYTAC-Gem compound can significantly inhibit the tumor growth of a KPC pancreatic cancer mouse model, molecular mechanism research further reveals that the LYTAC-Gem compound can down-regulate the expression of PD-L1 protein in tumor tissues, and it is indicated that the LYTAC-Gem compound has the potential to activate an anti-tumor immune response, and the application provides a novel targeted delivery strategy for overcoming the toxic side effects and tumor drug resistance of gemcitabine.

The present invention provides methods for treatment of high-risk non-muscle invasive bladder cancer that is unresponsive to BCG therapy by locally administering gemcitabine to the bladder. Also provided herein are kits and articles of manufacture for treating high-risk non-muscle invasive bladder cancer that is unresponsive to BCG.

The present invention relates to the field of biomedicine. Disclosed herein is interferon-based method and pharmaceutical combination for treating cancer. In particular, the present invention relates to an interferon-based method for treating cancer, comprising i) intermittently administering an interferon-based therapeutic agent, and ii) administering an additional anticancer agent, preferably, Gemcitabine, to a subject, wherein said additional anti-cancer agent is administered after the first administration of said intermittent administration of an interferon-based therapeutic agent. The present invention also relates to a pharmaceutical combination for use in said method.

An object of the present invention is to provide a combined pharmaceutical formulation obtained by combining a liposome composition and an immune checkpoint inhibitor, in which gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes liposomes each having an inner water phase, and an aqueous solution constituting an outer water phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.

The invention belongs to the technical field of medicines, and relates to a prodrug designed based on a tumor LAT1 transporter and a preparation method of the prodrug, in particular to a gemcitabine analogue prodrug taking LAT1 as a target spot and a preparation method of the gemcitabine analogue prodrug. The invention relates to a derivative shown as a total general formula and sub general formulas 1-3, and pharmaceutically acceptable salt, hydrate, solvate or prodrug structure thereof, wherein X, Y, Dug and Amino acid are defined in the specification and claims. The series of prodrugs provided by the invention can realize synchronous delivery of chemotherapeutic drugs and lactic acid transport inhibitors in tumors through LAT1 mediation. The lactic acid transport inhibitor is used for inducing apoptosis of hypoxic cells and sensitizing chemotherapeutic drugs, and the lactic acid transport inhibitor and the chemotherapeutic drugs have a synergistic effect.

The present invention provides a method for manufacturing a drug-coated balloon and a drug-coated balloon obtained by the method. The method for manufacturing a drug-coated balloon is used to apply a drug coating on the surface of a balloon body prepared in advance and in a filled and expanded state, and the anti-proliferative drug component in the drug coating is one or more of nimustine, carmustine, 5-fluorouracil, fluguanosine, gemcitabine, daunorubicin, doxorubicin, paclitaxel, vinblastine, topotecan, aminoglutethimide, sirolimus, everolimus, and zotarolimus. The drug-coated balloon prepared by the method can effectively ensure that when the balloon enters the human body, the thickness of the drug coating on the balloon surface is more uniform and consistent, thereby improving the clinical use effect.

The present disclosure concerns methods for treating pancreatic cancer cells with a combination of gemcitabine (GEM) and SapC-DOPS. In some aspects, GEM treatment preferentially targets G1 phase cells which are low in surface phosphatidylserine (PS), resulting in an increased median surface PS level of PDAC cells. Inversely, SapC-DOPS targets high surface PS cells which are predominantly in the G2 / M phase. In other aspects, a combination therapy on tumors in vivo with SapC-DOPS and GEM or Abraxane® (Abr) / GEM is demonstrated to significantly inhibit tumor growth and increases survival.

Provided include methods, compositions and kits for treating ovarian cancer (e.g., platinum-resistant ovarian cancer) in a subject. The method can comprise administration of a combination of a PLK1 inhibitor and a DNA-damaging agent (e.g., carboplatin or gemcitabine) to the subject in a manner sufficient to inhibit progression of the cancer.

To provide amphiphilic gemcitabine prodrugs or amphiphilic prodrugs of other biologically active molecules with the capacity to make liquid crystalline nanostructured nanoparticles, and uses thereof to treat animals, including humans.SOLUTION: The invention provides compounds such as 2'-deoxy-2',2'-difluoro-N4-(((cis-9, octadecenyl)oxy)carbonyl) cytidine (Gem-oleyl).SELECTED DRAWING: None

The present invention provides a method for treating pancreatic cancer. The method comprises administering an effective amount of dapanstril to a subject in need thereof. The preferred route of administration of dapanstril is oral administration. The present invention also provides a combination therapy for pancreatic cancer by administering dapanstril and gemcitabine to a patient in need thereof.

The present disclosure provides double stranded nucleic acid compositions incorporating uracil, gemcitabine, and methotrexate (MTX). More specifically, the present disclosure reveals that modification of a double-stranded microRNA nucleotide sequence with 5-fluorouracil, gemcitabine, and methotrexate (MTX) enhances the therapeutic efficacy and tumor specificity of tumor suppression. Thus, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-fluorouracil, gemcitabine, and methotrexate (MTX) incorporated into their nucleic acid sequences, as well as methods of using the same. The disclosure further provides pharmaceutical compositions (e.g., formulations) comprising the modified nucleic acid compositions, and methods for treating cancer, e.g., pancreatic cancer. The method is a platform technology which can be applied to other tumor suppressor genes miRNA and siRNA.

The invention provides a drug-loaded gelatin nanogel, a bionic nanogel, a preparation method of the drug-loaded gelatin nanogel, a preparation method of the bionic nanogel, a combined drug and application of the bionic nanogel, and belongs to the technical field of biological medicine. According to the invention, all-transretinoic acid, pirfenidone and gelatin react to form drug-loaded gelatin nanogel, and the drug-loaded gelatin nanogel can synergistically inhibit the activation of pancreatic stellate cells and block a fibrosis-promoting signal channel, so that the reversion of a pancreatic cancer fibrosis microenvironment is realized; meanwhile, the activated pancreatic stellate cell membrane is coated with the drug-loaded gelatin nanogel to construct the bionic nanogel, so that the bionic nanogel has active targeting property, and the delivery efficiency and the treatment effect of the drug are remarkably improved; and the drug-loaded gelatin nanogel, the bionic nanogel and the chemotherapeutic drug are combined for treating pancreatic cancer, so that a remarkable anti-tumor effect is achieved, and the combined treatment of the bionic nanogel and gemcitabine has a synergistic anti-tumor effect. The gel provided by the invention realizes effective regulation and control of a pancreatic cancer dense fibrosis microenvironment, and provides a feasible new strategy for treatment of pancreatic cancer.

The invention relates to a gemcitabine prodrug nano assembly as well as a preparation method and application thereof, and belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations. The gemcitabine-vitamin E prodrug is obtained by connecting gemcitabine and vitamin E by taking thiodiglycolic anhydride as a connecting chain, and the specific structure is as shown in a general formula (I). The prodrug disclosed by the invention can construct and form a gemcitabine-vitamin E prodrug nano assembly with good self-assembly stability and chemical stability based on a Core-matured technology, and specifically releases gemcitabine in a high-oxidation environment in tumor cells, so that the curative effect of gemcitabine is effectively improved, the toxic and side effects of gemcitabine are reduced, and the preparation method is suitable for clinical application. And a new strategy and choice are provided for developing a high-efficiency and low-toxicity chemotherapy preparation.

The present invention is directed to polymer-drug conjugates and / or compositions and / or nanoparticles comprising anti-cancer agents. The present invention is also directed to polymer- drug conjugates and / or compositions comprising docetaxel and the administration of docetaxel derivatives for the treatment of a number of diseases. The present invention is also directed to polymer-drug conjugates and / or compositions comprising gemcitabine or combretastatin A4 for the treatment of a number of diseases.

The present invention provides methods, devices and kits relating to treating lower tract urothelial carcinomas with an antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treating lower tract urothelial carcinomas with an antimetabolite (such as gemcitabine) and an immunomodulatory agent.

A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.